Oragenics Inc

Opportunity

Upcoming catalysts

Pre-earnings brief

Oragenics Inc (OGEN) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of June 30, 2024, investor ID 466 acquired 21,059 shares, representing a portfolio weight of approximately 4.96e-07% and a value of $0.022 million. This activity was detected on June 28, 2026, and stands as the primary signal of interest in the absence of other cross-source signals or prior historical deltas for comparison. The significance of this holder change is contextualized by the company’s current structural profile. Oragenics currently reports zero officers and zero analyst coverage, indicating a lack of public-facing executive leadership and professional market analysis. Furthermore, the company holds no index memberships, suggesting it is not included in major market benchmarks. These factors highlight the early-stage or dormant nature of the entity’s public market presence. Despite the minimal scale of the recent investment, the addition of a new holder is notable given the company’s limited top holder count of five. The acquisition of shares by investor ID 466 represents a tangible shift in ownership distribution, even if the absolute value remains low. This activity provides a rare data point for a company that otherwise lacks analyst attention or index inclusion. This synthesis relies on the initial analysis of the ticker, as no prior basis exists for computing changes in holder activity or other metrics. The data underscores the importance of monitoring even small capital movements in companies with sparse public information, such as Oragenics, where every new holder may signal emerging interest or strategic positioning. The lack of additional signals or sagas further isolates this holder change as the sole material event for the period.

Signals & dispatch

Composite-score breakdown

Synthesis

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Sell-side observations

Themes

ESG

Risk factors

• Filings reference going-concern or substantial-doubt language.
• Source documents mention dilution or offering risk.

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

• Spencer JohnChief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 55 900 @ $0,59grant · 2026-07-01
• Huffman JanetCEO and CFO · Employee Stock Option (right to buy) → Common StockAcquired 250 000 @ $0,93grant · 2025-12-11
• DUNTON ALAN WDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11
• Giordano NatashaDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 38 320 @ $1,03grant · 2025-12-11
• Giordano NatashaDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11
• Telling FredDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11
• GANDOLFO JOHN PDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11
• KOSKI ROBERT CDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11
• POPE CHARLES LDirector · Non-Employee Director Option (Right to Buy) → Common StockAcquired 125 000 @ $0,93grant · 2025-12-11

Actions

Ask Handelsavisen